ThromboGenics NV of Belgium has partnered its lead drug for sight impairment with the Alcon division of Novartis for potential fees of €375 million. Under the agreement, Alcon obtains marketing rights for Ocriplasmin (microplasmin) outside the US.
Elan Corporation Plc of Ireland said that it has received a net $381 million from the sale on the US Nasdaq market of 76% of its holdings in Alkermes Plc, a biopharmaceutical company with headquarters in Dublin and an R&D center in Waltham, Massachusetts, US.
Galápagos NV has secured a lucrative licensing deal with Abbott Laboratories Inc for an oral Janus kinase (JAK) inhibitor for rheumatoid arthritis just three months after the drug showed efficacy in a four-week Phase 2a proof-of-concept study.
Paion AG has decided to sell its remaining rights to the candidate stroke drug, desmoteplase, to H. Lundbeck A/S in order to bolster its cash position and concentrate on therapies for anaesthesia and critical care. The deal will yield €20.1 million.
Venture-capital backed ArGEN-X BV of the Netherlands has entered into an antibody discovery and development agreement with Shire Plc that will use its technology to isolate and characterise antibodies against targets related to rare, genetic diseases.
Angiochem Inc of Canada has secured a new global collaboration with GlaxoSmithKline Plc to develop a new enzyme replacement therapy for a lysosomal storage disease. The deal features an upfront payment of up to $31.5 million.
Novartis has agreed to pay privately-owned Enanta Pharmaceuticals Inc $34 million upfront, plus potential milestones of $406 million, for exclusive rights to a compound to treat hepatitis C. The compound is poised to enter clinical development.
GlaxoSmithKline PLC has decided to exercise an option giving it the right to exclusively license from Galápagos NV two compounds against immuno-inflammatory diseases. The compounds are part of an alliance dating from 2006.
Algeta ASA of Norway has successfully raised more than $45 million in a private share placement which will support the registration and commercialisation of its lead product, Alpharadin, for the treatment of cancer patients with bone metastases.
EOS imaging SA, which has developed a three-dimensional imaging system for orthopaedic investigations, has raised €38 million in an initial public offering on the Paris NYSE Euronext Exchange. The French company said its offering was 3.8 times oversubscribed at €6.87 per share.